Skip to main content

Table 3 ALT response, by therapy group

From: Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]

ALT response N (%) Group A Interferon and Ribavirin (n = 40) Group B Ribavirin (n = 40) Group C Placebo (n = 37)
On therapy1 23 (58%) 9 (23%) 3 (8.1%)
End of treatment2 19 (48%) 4 (10%) 2 (5.4%)
End of follow up3 7 (18%) 1 (2.7%) 1 (2.5%)
  1. 1normal ALT on at least two occasions with at least 1 month interval, p < 0.01 (Pearson Chi-square). 2normal ALT at week 24 and at least one month earlier, p < 0.01 (Pearson Chi-square). 3persistently normal ALT levels during 24 weeks follow up, p = 0.02 (Pearson Chi-square).